Trials / Completed

CompletedNCT00002217

A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: —

Sponsor: Glaxo Wellcome · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.

Detailed description

In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.

Conditions

HIV Infections

Interventions

Type	Name	Description
DRUG	Lamivudine/Zidovudine
DRUG	Abacavir sulfate
DRUG	Amprenavir

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002217. Inclusion in this directory is not an endorsement.